Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the month of January 2022, with the report signed on January 17, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| January 13, 2022 | Ordinary Shares (25p each) | £16.3446 | 1,607 shares | London Stock Exchange (XLON) |
Note: Total volume is the aggregate of individual transactions listed below.
Material Changes and Transaction Details
The filing details five separate transactions involving the acquisition of ordinary shares. All transactions were executed on January 13, 2022, at a uniform price of £16.3446 per share. The nature of all transactions was the acquisition of shares following the re-investment of dividends paid to shareholders on that date.
- Ms S Jackson (SVP, Global Communications & CEO Office): Acquired 17 shares.
- Mr D Jackson (PCA of Ms S Jackson): Acquired 17 shares.
- Ms V Whyte (Company Secretary): Acquired 29 shares.
- Mr I Whyte (PCA of Ms V Whyte): Acquired 1,076 shares.
- Ms D Connor (PCA of Mr R G Connor, President, Vaccines & Global Health): Acquired 487 shares.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of share transactions.
Key Facts for Investor Verification
- Verify the dividend reinvestment plan (DRIP) terms applicable to GSK shareholders for the January 2022 payment date.
- Confirm the market price of GSK ordinary shares on January 13, 2022, to validate the transaction price of £16.3446.
- Note that the largest single transaction (1,076 shares) was executed by Mr I Whyte, a person closely associated with the Company Secretary.
- Ensure these transactions are consistent with the company's insider trading policy and applicable UK market abuse regulations.